[HTML][HTML] β Cell function and plasma insulin clearance in people with obesity and different glycemic status
B Mittendorfer, BW Patterson, GI Smith… - The Journal of …, 2022 - Am Soc Clin Investig
The Journal of clinical investigation, 2022•Am Soc Clin Investig
Background It is unclear how excess adiposity and insulin resistance affect β cell function,
insulin secretion, and insulin clearance in people with obesity. Methods We used a
hyperinsulinemic-euglycemic clamp procedure and a modified oral glucose tolerance test to
evaluate the interrelationships among obesity, insulin sensitivity, insulin kinetics, and
glycemic status in 5 groups of individuals: normoglycemic lean and obese individuals with
(a) normal fasting glucose and normal glucose tolerance (Ob-NFG-NGT),(b) NFG and …
insulin secretion, and insulin clearance in people with obesity. Methods We used a
hyperinsulinemic-euglycemic clamp procedure and a modified oral glucose tolerance test to
evaluate the interrelationships among obesity, insulin sensitivity, insulin kinetics, and
glycemic status in 5 groups of individuals: normoglycemic lean and obese individuals with
(a) normal fasting glucose and normal glucose tolerance (Ob-NFG-NGT),(b) NFG and …
Background
It is unclear how excess adiposity and insulin resistance affect β cell function, insulin secretion, and insulin clearance in people with obesity.
Methods
We used a hyperinsulinemic-euglycemic clamp procedure and a modified oral glucose tolerance test to evaluate the interrelationships among obesity, insulin sensitivity, insulin kinetics, and glycemic status in 5 groups of individuals: normoglycemic lean and obese individuals with (a) normal fasting glucose and normal glucose tolerance (Ob-NFG-NGT), (b) NFG and impaired glucose tolerance (Ob-NFG-IGT), (c) impaired fasting glucose and IGT (Ob-IFG-IGT), or (d) type 2 diabetes (Ob-T2D).
Results
Glucose-stimulated insulin secretion (GSIS), an assessment of β cell function, was greater in the Ob-NFG-NGT and Ob-NFG-IGT groups than in the lean group, even when insulin sensitivity was matched in the obese and lean groups. Insulin sensitivity, not GSIS, was decreased in the Ob-NFG-IGT group compared with the Ob-NFG-NGT group, whereas GSIS, not insulin sensitivity, was decreased in the Ob-IFG-IGT and Ob-T2D groups compared with the Ob-NFG-NGT and Ob-NFG-IGT groups. Insulin clearance was directly related to insulin sensitivity and inversely related to the postprandial increase in insulin secretion and plasma insulin concentration.
Conclusion
Increased adiposity per se, not insulin resistance, enhanced insulin secretion in people with obesity. The obesity-induced increase in insulin secretion, in conjunction with a decrease in insulin clearance, sufficiently raised the plasma insulin concentrations needed to maintain normoglycemia in individuals with moderate, but not severe, insulin resistance. A deterioration in β cell function, not a decrease in insulin sensitivity, was a determinant of IFG and ultimately leads to T2D.
CLINICAL TRIALS REGISTRATION
ClinicalTrials.gov NCT02706262, NCT04131166, and NCT01977560.
FUNDING
NIH (P30 DK056341, P30 DK020579, and UL1 TR000448); American Diabetes Association (1-18-ICTS-119); Longer Life Foundation; Pershing Square Foundation; and Washington University-Centene ARCH Personalized Medicine Initiative (P19-00559).
The Journal of Clinical Investigation